| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 35 | 2026 | 474 | 7.650 |
Why?
|
| Nanoparticles | 26 | 2026 | 299 | 5.930 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2025 | 2057 | 2.540 |
Why?
|
| Liposomes | 22 | 2019 | 197 | 1.990 |
Why?
|
| X-Ray Microtomography | 7 | 2025 | 101 | 1.750 |
Why?
|
| Placenta | 6 | 2025 | 495 | 1.740 |
Why?
|
| Gadolinium | 7 | 2019 | 110 | 1.700 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2026 | 3741 | 1.640 |
Why?
|
| Iodine | 5 | 2023 | 20 | 1.580 |
Why?
|
| Aortic Aneurysm | 2 | 2025 | 222 | 1.270 |
Why?
|
| Triiodobenzoic Acids | 5 | 2021 | 29 | 1.260 |
Why?
|
| Alzheimer Disease | 4 | 2026 | 877 | 1.090 |
Why?
|
| Neuroblastoma | 3 | 2022 | 547 | 0.930 |
Why?
|
| Animals | 58 | 2026 | 33660 | 0.910 |
Why?
|
| Mice | 42 | 2026 | 18160 | 0.890 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2022 | 150 | 0.830 |
Why?
|
| Aorta | 4 | 2025 | 522 | 0.810 |
Why?
|
| Disease Models, Animal | 16 | 2026 | 4639 | 0.800 |
Why?
|
| Phantoms, Imaging | 5 | 2022 | 141 | 0.780 |
Why?
|
| Aortic Rupture | 2 | 2021 | 112 | 0.750 |
Why?
|
| Plaque, Amyloid | 2 | 2020 | 65 | 0.740 |
Why?
|
| Aortography | 2 | 2021 | 152 | 0.730 |
Why?
|
| Image Enhancement | 4 | 2010 | 159 | 0.660 |
Why?
|
| Sarcoma | 2 | 2022 | 218 | 0.630 |
Why?
|
| Drug Delivery Systems | 4 | 2019 | 218 | 0.630 |
Why?
|
| Amyloid | 1 | 2020 | 73 | 0.620 |
Why?
|
| Brain Neoplasms | 5 | 2019 | 1305 | 0.610 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 215 | 0.590 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1547 | 0.590 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 336 | 0.590 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2016 | 135 | 0.500 |
Why?
|
| Apolipoproteins E | 4 | 2025 | 187 | 0.500 |
Why?
|
| Blood-Brain Barrier | 3 | 2019 | 153 | 0.500 |
Why?
|
| Atherosclerosis | 2 | 2022 | 947 | 0.460 |
Why?
|
| Dog Diseases | 1 | 2016 | 58 | 0.460 |
Why?
|
| Tumor Burden | 4 | 2021 | 237 | 0.450 |
Why?
|
| Physical Conditioning, Animal | 2 | 2025 | 84 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 4691 | 0.420 |
Why?
|
| Mice, Transgenic | 6 | 2026 | 2330 | 0.400 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 1366 | 0.390 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 706 | 0.390 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 1800 | 0.380 |
Why?
|
| Drug Carriers | 5 | 2019 | 118 | 0.370 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2009 | 161 | 0.370 |
Why?
|
| Photons | 2 | 2025 | 60 | 0.350 |
Why?
|
| Diet, High-Fat | 2 | 2025 | 268 | 0.350 |
Why?
|
| Glioblastoma | 2 | 2015 | 372 | 0.320 |
Why?
|
| Indocyanine Green | 3 | 2023 | 51 | 0.310 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 45 | 0.310 |
Why?
|
| Particle Size | 3 | 2025 | 134 | 0.300 |
Why?
|
| Rats | 7 | 2020 | 3372 | 0.300 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 235 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 4 | 2019 | 227 | 0.300 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 204 | 0.290 |
Why?
|
| Theranostic Nanomedicine | 2 | 2020 | 8 | 0.280 |
Why?
|
| Aortic Diseases | 2 | 2025 | 187 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 356 | 0.270 |
Why?
|
| Optical Imaging | 2 | 2018 | 76 | 0.260 |
Why?
|
| Pregnancy | 6 | 2025 | 7390 | 0.240 |
Why?
|
| Peptide Fragments | 2 | 2020 | 687 | 0.240 |
Why?
|
| Brain | 5 | 2026 | 3146 | 0.230 |
Why?
|
| Spine | 1 | 2007 | 150 | 0.230 |
Why?
|
| Humans | 28 | 2025 | 130085 | 0.230 |
Why?
|
| Nanomedicine | 3 | 2020 | 28 | 0.230 |
Why?
|
| Cell Line, Tumor | 8 | 2022 | 3713 | 0.230 |
Why?
|
| Moyamoya Disease | 1 | 2025 | 41 | 0.220 |
Why?
|
| Neoplasms | 5 | 2020 | 2975 | 0.210 |
Why?
|
| Ferrosoferric Oxide | 1 | 2025 | 25 | 0.210 |
Why?
|
| Oxidative Phosphorylation | 1 | 2025 | 141 | 0.210 |
Why?
|
| Mice, Nude | 6 | 2019 | 699 | 0.210 |
Why?
|
| Heart | 2 | 2025 | 659 | 0.210 |
Why?
|
| Cardiovascular Diseases | 3 | 2025 | 2107 | 0.210 |
Why?
|
| Female | 20 | 2025 | 70246 | 0.210 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2025 | 171 | 0.200 |
Why?
|
| Cadmium Compounds | 1 | 2023 | 1 | 0.200 |
Why?
|
| Quantum Dots | 1 | 2023 | 16 | 0.190 |
Why?
|
| Actins | 1 | 2025 | 313 | 0.190 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 419 | 0.190 |
Why?
|
| Folic Acid | 1 | 2005 | 269 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 719 | 0.190 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2019 | 14 | 0.180 |
Why?
|
| Adventitia | 1 | 2022 | 4 | 0.180 |
Why?
|
| Nanotechnology | 2 | 2014 | 49 | 0.180 |
Why?
|
| Placenta Accreta | 1 | 2025 | 172 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 283 | 0.180 |
Why?
|
| Tissue Distribution | 2 | 2020 | 362 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 76 | 0.180 |
Why?
|
| Models, Biological | 2 | 2011 | 1375 | 0.170 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 105 | 0.170 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 65 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 175 | 0.170 |
Why?
|
| Radiometry | 1 | 2021 | 49 | 0.170 |
Why?
|
| Molecular Imaging | 2 | 2013 | 58 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2021 | 26 | 0.170 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 74 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 711 | 0.160 |
Why?
|
| Presenilin-1 | 1 | 2020 | 51 | 0.160 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 83 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2020 | 47 | 0.160 |
Why?
|
| Thrombospondin 1 | 1 | 2020 | 23 | 0.160 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2020 | 41 | 0.160 |
Why?
|
| Doxorubicin | 2 | 2019 | 289 | 0.160 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2020 | 36 | 0.160 |
Why?
|
| Angiotensin II | 1 | 2021 | 131 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2025 | 527 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1109 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 191 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 89 | 0.160 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2020 | 113 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2005 | 996 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1604 | 0.150 |
Why?
|
| Radiographic Image Enhancement | 2 | 2011 | 38 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 55 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2022 | 373 | 0.150 |
Why?
|
| Heterografts | 2 | 2017 | 189 | 0.150 |
Why?
|
| Cytosol | 1 | 2019 | 135 | 0.150 |
Why?
|
| Blood Volume | 1 | 2019 | 73 | 0.150 |
Why?
|
| Silicon Dioxide | 1 | 2019 | 27 | 0.150 |
Why?
|
| Fibronectins | 1 | 2019 | 99 | 0.150 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2019 | 20 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 267 | 0.150 |
Why?
|
| Fluorine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Male | 12 | 2025 | 64386 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 122 | 0.140 |
Why?
|
| Endothelial Cells | 2 | 2020 | 520 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2290 | 0.140 |
Why?
|
| Hindlimb | 1 | 2018 | 72 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 613 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 390 | 0.140 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 26 | 0.140 |
Why?
|
| Angiography | 1 | 2018 | 181 | 0.140 |
Why?
|
| Fluorocarbons | 1 | 2018 | 66 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 65 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 1001 | 0.130 |
Why?
|
| Machine Learning | 1 | 2021 | 380 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 598 | 0.130 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 358 | 0.130 |
Why?
|
| Skull | 1 | 2018 | 148 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2025 | 697 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 705 | 0.120 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 21 | 0.120 |
Why?
|
| Magnetite Nanoparticles | 1 | 2016 | 8 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 808 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 979 | 0.120 |
Why?
|
| Ligands | 3 | 2019 | 480 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 2016 | 109 | 0.110 |
Why?
|
| Mice, Knockout | 5 | 2025 | 3810 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1589 | 0.110 |
Why?
|
| Time Factors | 4 | 2021 | 6165 | 0.110 |
Why?
|
| Dogs | 1 | 2016 | 615 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2191 | 0.110 |
Why?
|
| DNA | 1 | 2019 | 1398 | 0.110 |
Why?
|
| Ferric Compounds | 3 | 2020 | 39 | 0.100 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2013 | 13 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 883 | 0.100 |
Why?
|
| Nanocapsules | 1 | 2013 | 8 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 448 | 0.100 |
Why?
|
| Liver | 2 | 2021 | 1783 | 0.090 |
Why?
|
| Fetus | 1 | 2016 | 567 | 0.090 |
Why?
|
| Microvessels | 1 | 2013 | 58 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 201 | 0.090 |
Why?
|
| Uterus | 1 | 2016 | 540 | 0.090 |
Why?
|
| Coordination Complexes | 1 | 2011 | 9 | 0.090 |
Why?
|
| Drug Compounding | 1 | 2011 | 38 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 481 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 37 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2021 | 4645 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 254 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2011 | 369 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 80 | 0.080 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2023 | 160 | 0.080 |
Why?
|
| Genotype | 2 | 2025 | 2588 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 80 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2009 | 587 | 0.070 |
Why?
|
| Iopamidol | 1 | 2009 | 3 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 975 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1205 | 0.070 |
Why?
|
| Lung | 1 | 2016 | 1531 | 0.070 |
Why?
|
| Mammography | 1 | 2009 | 121 | 0.070 |
Why?
|
| Iohexol | 1 | 2007 | 19 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 7 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1874 | 0.060 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 17 | 0.060 |
Why?
|
| Veins | 1 | 2007 | 95 | 0.060 |
Why?
|
| Cardiology | 1 | 2012 | 514 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 103 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 94 | 0.060 |
Why?
|
| Artifacts | 1 | 2007 | 99 | 0.060 |
Why?
|
| Arteries | 1 | 2007 | 209 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 182 | 0.060 |
Why?
|
| Aged | 1 | 2024 | 20821 | 0.060 |
Why?
|
| Niacinamide | 1 | 2025 | 31 | 0.060 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2005 | 44 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 140 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 2076 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 232 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 182 | 0.050 |
Why?
|
| Glycolysis | 1 | 2025 | 173 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17541 | 0.050 |
Why?
|
| Apolipoprotein E3 | 1 | 2023 | 8 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 2597 | 0.050 |
Why?
|
| Apolipoprotein E2 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2025 | 224 | 0.050 |
Why?
|
| Apoptosis | 2 | 2021 | 1826 | 0.050 |
Why?
|
| Gallium | 1 | 2023 | 1 | 0.050 |
Why?
|
| Tellurium | 1 | 2023 | 2 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 51 | 0.050 |
Why?
|
| Arsenicals | 1 | 2023 | 17 | 0.050 |
Why?
|
| Bismuth | 1 | 2023 | 84 | 0.050 |
Why?
|
| Vimentin | 1 | 2022 | 59 | 0.050 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2022 | 57 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 304 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 246 | 0.040 |
Why?
|
| Cell Movement | 1 | 2025 | 873 | 0.040 |
Why?
|
| Monoterpenes | 1 | 2020 | 7 | 0.040 |
Why?
|
| Activin Receptors, Type II | 1 | 2020 | 30 | 0.040 |
Why?
|
| ADAM10 Protein | 1 | 2020 | 13 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 345 | 0.040 |
Why?
|
| Activin Receptors, Type I | 1 | 2020 | 33 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 49 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2020 | 58 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 86 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 134 | 0.040 |
Why?
|
| Mitochondria | 1 | 2025 | 768 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 378 | 0.040 |
Why?
|
| tau Proteins | 1 | 2022 | 258 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 44 | 0.040 |
Why?
|
| Placentation | 1 | 2019 | 59 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 117 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 72 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 61 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 823 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2018 | 96 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 975 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 83 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 351 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2025 | 1906 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2009 | 99 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 267 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 298 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 449 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 552 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 500 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 15 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 583 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 82 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 758 | 0.030 |
Why?
|
| Gestational Age | 1 | 2019 | 1210 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 1060 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1649 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 2013 | 36 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 2008 | 0.020 |
Why?
|
| Motion | 1 | 2013 | 37 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 631 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 3358 | 0.020 |
Why?
|
| Microcirculation | 1 | 2013 | 104 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2016 | 381 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 213 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2462 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 304 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 27 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 32 | 0.020 |
Why?
|
| Hydrodynamics | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 5034 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 81 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 54 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 409 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 765 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 105 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 820 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 659 | 0.020 |
Why?
|
| Carcinoma | 1 | 2011 | 283 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2554 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 98 | 0.020 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 29 | 0.020 |
Why?
|
| Rabbits | 1 | 2007 | 572 | 0.010 |
Why?
|
| Nanostructures | 1 | 2006 | 68 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2885 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 145 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 15005 | 0.010 |
Why?
|
| Adult | 1 | 2025 | 31011 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 437 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2891 | 0.010 |
Why?
|